After Boehringer Ingelheims’s initial rejection of its new lung cancer drug, Vargatef, the company submitted new analyses of clinical trial data and lowered the overall cost to the NHS. After reviewing Vargatef again, the National Institute for Health and Care Excellence (NICE) is now backing the treatment as being cost-effective. Read more here. (Source: Ben Adams, PMLiVE, 6/4/15)
You are here: / / How Did Boehringer Turn a NICE Rejection into a Recommendation?